MK-0354

• Description :

  MK-0354 is a specific GPR109a receptor agonist with EC50 values of 1.65 μM and 1.08 μM for hGPR109a and mGPR109a, respectively. MK-0354 can be used in liver cancer research[1][2][3][4].

• UNSPSC :

  12352005

• Hazard Statement :

  H315-H319-H320

• Target :

  GPR109A

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/MK-0354.html

• Purity :

  99.73

• Solubility :

  DMSO : ≥ 36 mg/mL

• Smiles :

  C12=C(CCC2)C(C3=NN=NN3)=NN1

• Molecular Formula :

  C7H8N6

• Molecular Weight :

  176.18

• Precautions :

  P264-P280-P302+P352-P305+P351+P338-P362

• References & Citations :

  [1]Semple G, et al. 3- (1H-Tetrazol-5-yl) -1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354) : A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice. J. Med. Chem., 2008, 51 (16), pp 5101-5108|[2]Lai E1, et al. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol. 2008 Oct;2 (5) :375-383.|[3]Walters RW, et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest. 2009 May;119 (5) :1312-21. |[4]Yang Y, et al. Dietary vitamin B3 supplementation induces the antitumor immunity against liver cancer via biased GPR109A signaling in myeloid cell. Cell Rep Med. 2024 Sep 17;5 (9) :101718.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [851776-28-8]